Skjodt N M, Davies N M
Department of Medicine, University of Calgary, Alberta, Canada.
Clin Pharmacokinet. 1998 Jun;34(6):421-8. doi: 10.2165/00003088-199834060-00001.
Lornoxican (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5'-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation. Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours. Lornoxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of lornoxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. The effects of lornoxicam concentration on its therapeutic and toxicological properties have not yet been extensively reported. Lornoxicam, like other NSAIDs, appears to interact with warfarin, sulphonylureas, digoxin and furosemide.
氯诺昔康是一种昔康类非甾体抗炎药。与其他昔康类药物不同，氯诺昔康的血浆半衰期相对较短（3至5小时）。氯诺昔康经生物转化为5'-羟基氯诺昔康后被清除，5'-羟基氯诺昔康不会进行肝肠循环。葡萄糖醛酸结合代谢物通过尿液和粪便排出，半衰期约为11小时。氯诺昔康及其代谢物与血浆白蛋白广泛结合。在滑液中可达到相当高浓度的氯诺昔康，滑液是慢性炎症性关节病的假定作用部位。氯诺昔康浓度对其治疗和毒理学特性的影响尚未有广泛报道。与其他非甾体抗炎药一样，氯诺昔康似乎会与华法林、磺脲类、地高辛和呋塞米相互作用。
